[Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review].

This article is devoted to the problem of the effectiveness of therapy of recurrent polyposis rhinosinusitis and the choice of the most effective drug from the group of monoclonal antibodies. The wide prevalence of the disease, as well as the low level of effectiveness of existing treatment methods, such as glucocorticosteroid (topical and topical) therapy, antibacterial therapy and available surgical methods of treatment (polypotomy, endoscopic polysinusitomy) allow us to conclude that the existing methods of treatment for recurrent polyposis process do not allow to achieve a stable positive result. Various undesirable phenomena with prolonged use of steroidal drugs, as well as the need for repeated rhinosinusosurgery in case of recurrence of this process, make doctors-otorhinolaryngologists around the world to look for new treatment options for polyposis rhinosinusitis, one of these methods is the use of monoclonal antibodies.

Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series.

Data on hereditary angioedema with normal C1 inhibitor levels are currently limited. To date, only one Italian family with HAE-MYOF has been described, comprising exclusively female members. The angioedema (AE) of head and neck area with the teenage onset, triggered by menses and high fever episodes were identified.

Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?

Background: Robust data are essential for clinical and epidemiological research, yet in chronic spontaneous urticaria (CSU), certain patient groups, such as the elderly or comorbid patients, are often underrepresented. In clinical trials, strict inclusion and exclusion criteria frequently limit recruitment, making it difficult to achieve sufficient statistical power. Similarly, real-world observational studies may lack sufficient sample sizes for robust analysis.

Рrospective multicenter study of treatment efficacy, safety, and quality of life in a large cohort of patients with inborn errors of immunity receiving subcutaneous immunoglobulin by the rapid push method.

Subcutaneous immunoglobulin (SCIG) preparations are widely used in patients with inborn errors of immunity (IEI), with proven efficacy and good tolerance. We assessed treatment efficacy, safety, and quality of life in a large cohort of IEI patients who switched from intravenous immunoglobulin (IVIG) to SCIG. Our observational study included 200 patients aged 1-65 years with IEI.

[Psychosomatic sets of symptoms in schizotypal personality disorder].

Objective: To establish the functional activity of pseudoallergy sets of symptom complexes manifesting as a part of the schizotypal personality disorder.

Material And Methods: The study sample included 23 cases with manifestations resembling the clinical presentation of allergic dermatoses and skin symptoms of allergic diseases with no signs of somatic-related allergic sets of symptoms (medical history/laboratory studies). The patients were examined using clinical, laboratory, and psychometric methods followed by statistical data processing.